BILL ANALYSIS

S1782

NEUTRAL

Charlotte Woodward Organ Transplant Discrimination Prevention Act

S1782 (Charlotte Woodward Organ Transplant Discrimination Prevention Act) has been assessed with a neutral outlook for investors. The primary sectors impacted are Healthcare. View the full bill text on Congress.gov.

neutral

Market Sentiment

4/10

Impact Score

Sectors Impacted

Key Takeaways for Investors

S.1782 is a regulatory compliance bill, not a funding bill

Transplant hospitals and providers must adjust eligibility protocols

Bipartisan support increases likelihood of passage

How S1782 Affects the Market

The bill is neutral for healthcare sector stocks in the near term. No direct financial impact is authorized. Investors should monitor floor action and potential amendments. The regulatory burden is modest and unlikely to materially affect earnings for large-cap healthcare companies like UNH or JNJ.

Bill Details

Metric	Value
Bill Number	S1782
Market Sentiment	neutral
Event Date	June 17, 2026
Affected Sectors	Healthcare
Source	View on Congress.gov →

Summary

S.1782, the Charlotte Woodward Organ Transplant Discrimination Prevention Act, was reported favorably out of the Senate HELP Committee on June 17, 2026. The bill prohibits discrimination based on disability in organ transplant eligibility, requiring covered healthcare entities to make reasonable modifications. No direct funding is authorized; the impact is regulatory compliance for transplant hospitals and providers.

Full AI Market Analysis

1) What happened: On June 17, 2026, the Senate Committee on Health, Education, Labor, and Pensions ordered S.1782 to be reported favorably with an amendment. The bill, introduced by Sen. Moody (R-FL) with 21 cosponsors, now awaits floor action. It is a companion to H.R.1520 in the House. 2) Money trail: The bill does not authorize or appropriate any funding. It imposes a regulatory mandate on covered entities (hospitals, transplant centers, health care providers) to not discriminate on the basis of disability in organ transplant eligibility. 3) Structural winners and losers: The primary impact is on transplant hospitals and healthcare providers. HCA, UNH, and JNJ are affected as they operate or supply transplant services. The bill removes barriers for disabled individuals, potentially increasing the pool of eligible transplant candidates, which could drive modest volume growth for transplant-related drugs and services. 4) No real market data provided; analysis is based on legislative structure. 5) Timeline: The bill must pass the full Senate, then the House (companion H.R.1520 is also in committee), then be signed by the President. Given the bipartisan sponsorship (21 cosponsors including both parties), passage is plausible but not guaranteed.